Literature DB >> 23434194

The bisphosphonates: risks and benefits of long term use.

Anne Pernille Hermann1, Bo Abrahamsen.   

Abstract

Bisphosphonates are widely used globally as the main treatment for osteoporosis. Both safety and efficacy have only been rigorously evaluated in studies of relatively short duration (3-5 years), with smaller extension studies. The evidence for benefit beyond five years in intervention studies is limited and does not include proven efficacy against nonvertebral fractures. Observational studies suggest a sustained benefit against hip fractures. Bisphosphonates are stored in the skeleton for months to years, depending on the degree of bone turnover and the binding properties of the bisphosphonate in question. The effects of continued treatment on bone strength is not known but there are concerns that osteonecrosis of the jaw and atypical femur fractures may stem from long term bisphosphonate use.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23434194     DOI: 10.1016/j.coph.2013.02.002

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  5 in total

1.  Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up.

Authors:  M Belhassen; C B Confavreux; B Cortet; L Lamezec; M Ginoux; E Van Ganse
Journal:  Osteoporos Int       Date:  2016-10-20       Impact factor: 4.507

2.  Effect of aerobic exercise and raloxifene combination therapy on senile osteoporosis.

Authors:  Chengjin Zhao; Haibing Hou; Yutao Chen; Kai Lv
Journal:  J Phys Ther Sci       Date:  2016-06-28

3.  Bisphosphonates and primary breast cancer risk: an updated systematic review and meta-analysis involving 963,995 women.

Authors:  Yupeng Liu; Xiaosan Zhang; Hongru Sun; Shu Zhao; Yuxue Zhang; Dapeng Li; Qingyuan Zhang; Yashuang Zhao
Journal:  Clin Epidemiol       Date:  2019-07-18       Impact factor: 4.790

Review 4.  Osteoporosis pathogenesis and treatment: existing and emerging avenues.

Authors:  Shu Lin; Yan-Chuan Shi; Bo Liang; George Burley
Journal:  Cell Mol Biol Lett       Date:  2022-09-04       Impact factor: 8.702

Review 5.  Oral Administration of Quercetin or Its Derivatives Inhibit Bone Loss in Animal Model of Osteoporosis.

Authors:  Yue-Yue Huang; Zi-Hao Wang; Li-Hui Deng; Hong Wang; Qun Zheng
Journal:  Oxid Med Cell Longev       Date:  2020-10-27       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.